Sanofi announced on 4 January 2017 that the prescription combination drug Suliqua/iGlarLixi (insulin degludec + lixisenatide), which is indicated for the treatment of adult type 2 diabetes patients who are inadequately controlled by basal insulin (at a dose of less than 60 units per day) or by lixisenatide, is now available through US pharmacies. A post ad-hoc analysis of 736 patients with type 2 diabetes showed that Soliqua demonstrated significantly more effectiveness in controlling mealtime glucose than Lantus. Sanofi has reported that Soliqua will be available at a 'competitive price' in order to facilitate patient access. Soliqua was launched at a wholesale acquisition cost (WAC) price of USD 127 for a 300-unit pen (equivalent to USD 19.90 per day for the same dosage level as was administered to patients during clinical trials).